KRAS and non-small cell lung carcinoma: The data from a retrospective analysis suggested that co-occurring LKB1/STK11 mutations in KRAS mutant NSCLC may predict lower ORR, while data from another group showed no PFS or OS differences with or without concurrent mutant LKB1/STK11 and/or mutant KEPA1 in patients receiving combined chemoimmunotherapy and angiogenesis targeted agent (13, 81), raising the question whether angiogenesis targeted agent may help to overcome the challenge of the immune-inert state.